Corpus Intelligence IC Memo — PARKVIEW LAGRANGE HOSPITAL 2026-04-27 05:14 UTC
IC Memo — PARKVIEW LAGRANGE HOSPITAL
Investment Committee Memorandum | IN | 25 beds | Grade C | EBITDA uplift $3.1M
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 151323

PARKVIEW LAGRANGE HOSPITAL

LOCATIONLAGRANGE, IN·BEDS25·AS OFApril 27, 2026
C
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

PARKVIEW LAGRANGE HOSPITAL is a 25-bed suburban community hospital in LAGRANGE, IN with $42.1M in net patient revenue and a 5.2% operating margin. The hospital serves a payer mix of 21.7% Medicare, 2.5% Medicaid, and 75.8% commercial.

Thesis: Turnaround. Our ML models identify $3.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.2% to 12.6% (+736bps).

Net Revenue HCRIS$42.1M
Current EBITDA COMPUTED$2.2M
Operating Margin COMPUTED5.2%
Occupancy HCRIS34.6%
Revenue / Bed COMPUTED$1.7M
Net-to-Gross HCRIS29.5%
Distress Probability ML50.0%

2. Market Context & Competitive Position

171
IN Hospitals
-1.1%
State Median Margin
86
Comparable Hospitals

IN has 171 Medicare-certified hospitals with a median operating margin of -1.1%. The target's margin of 5.2% places it above the state median. Among 86 size-comparable peers (12-50 beds), the median margin is -5.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 86 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PARKVIEW LAGRANGE HOSPITAL (Target)IN25$42.1M5.2%
INDIANA ORTHOPAEDIC HOSPITAL LIN38$196.8M31.2%
ORTHOPAEDIC HOSPT.AT PARKVIEWIN37$175.7M36.8%
LUTHERAN MUSCULOSKELETAL CENTEIN39$168.9M25.0%
WITHAM MEMORIAL HOSPITALIN50$158.5M-11.6%
MAJOR HOSPITALIN46$156.9M-9.2%
HENRY COUNTY MEMORIAL HOSPITALIN48$137.8M-1.7%
MARGARET MARY COMMUNITY HOSPITIN25$124.5M-3.6%
KINGS DAUGHTERS HOSPITALIN43$123.4M-13.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$885K+210bp18mo
Cost to Collect4.5%2.5%$843K+200bp12mo
Denial Rate Reduction12.0%6.5%$834K+198bp12mo
A/R Days Reduction5200.0%3800.0%$513K+122bp9mo
Clean Claim Rate88.0%96.0%$27K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$885K
Cost to Collect
$843K
Denial Rate Reduction
$834K
A/R Days Reduction
$513K
Clean Claim Rate
$27K
Total EBITDA Uplift$3.1M
Current EBITDA$2.2M
+ RCM Uplift+$3.1M
Pro Forma EBITDA$5.3M
Current Margin5.2%
Pro Forma Margin12.6%
WC Released (1x)$1.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$3.4M$45.5M13.47x68.2%
Base (11x exit)10.0x11.0x$3.4M$51.1M15.14x72.2%
Bull Case9.0x11.0x$3.0M$62.5M20.55x83.1%
Bull (12x exit)9.0x12.0x$3.0M$69.1M22.72x86.8%
Bear Case11.0x10.0x$3.7M$28.9M7.78x50.7%
Bear (11x exit)11.0x11.0x$3.7M$33.0M8.88x54.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 34.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 50.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 86 hospitals with 12-50 beds
  • Same-state prioritization (n=87)
  • Comp margins: P25=-15.0% / P50=-5.6% / P75=6.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 27, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.